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Assessment of histological stage is an integral part of disease management in patients infected
with the hepatitis C virus (HCV). The aim of this study was to develop a model incorporating
objective clinical and laboratory parameters to estimate the probability of severe fibrosis
(i.e., Ishak fibrosis > 3) in previously untreated African American (AA) and Caucasian
American (CA) patients with HCV genotype 1. The Ishak fibrosis scores of 205 CA and 194
AA patients enrolled in the Viral Resistance to Antiviral Therapy of Chronic Hepatitis C
study (Virahep-C) were modeled using simple and multiple logistic regression. The model
was then validated in an independent cohort of 461 previously untreated patients with HCV.
The distribution of fibrosis scores was similar in the AA and CA patients as was the propor-
tion of patients with severe fibrosis (35% vs. 39%, P  .47). After accounting for the number
of portal areas in the biopsy, patient age, serum aspartate aminotransferase, alkaline phos-
phatase, and platelet count were independently associated with severe fibrosis in the overall
cohort, and the relationship with fibrosis was similar in both the AA and CA subgroups. The
area under the receiver operating characteristic curve (AUROC) of the Virahep-C model
(0.837) was significantly better than in other published models (P  .0003). The AUROC of
the Virahep-C model was 0.851 in the validation population. In conclusion, a model con-
sisting of widely available clinical and laboratory features predicted severe hepatic fibrosis
equally well in AA and CA patients with HCV genotype 1 and was superior to other pub-
lished models. The excellent performance of the Virahep-C model in an external validation
cohort suggests the findings are replicable and potentially generalizable. (HEPATOLOGY 2006;
44:925-935.)
Abbreviations: HCV, hepatitis C virus; Virahep-C, Viral Resistance to Antiviral Therapy of Chronic Hepatitis C; AST, aspartate aminotransferase; ALT, alanine
aminotransferase; APRI, AST to platelet ratio index; AUROC, area under the receiver operating characteristic curve.
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The prevalence of infection with hepatitis C virus(HCV) and the proportion with HCV genotype1 are significantly higher among African Ameri-
cans (AAs) than among Caucasian Americans (CAs).1 In
addition, there are differences in the proliferative response
of peripheral lymphocytes exposed to HCV antigens in
vitro, which may lead to less severe liver disease and a
poorer response to interferon therapy in AAs with HCV
than in CAs with HCV.2,3 However, information on the
severity and rates of hepatic fibrosis progression among
AAs with HCV has been limited because of the small
number of AA patients enrolled in previous studies.4-8
Assessment of the severity of hepatic fibrosis is an inte-
gral part of disease management in patients with chronic
HCV infection. Patients with minimal or mild fibrosis
appear to progress slowly, and antiviral treatment can be
safely delayed or withheld, particularly among patients
with HCV genotype 1.9 On the other hand, patients with
more severe fibrosis (e.g., bridging or septal fibrosis) may
progress to cirrhosis and should be prioritized for antiviral
treatment.10 Liver biopsy is the conventional means of
assessing hepatic fibrosis, but this invasive procedure is
expensive, potentially dangerous, and prone to sampling
error. Therefore, accurate, noninvasive means for estimat-
ing the severity of hepatic fibrosis are needed to help with
the management of the large number of HCV patients
worldwide.10 Panels of serum markers that reflect hepatic
fibrogenesis and fibrolysis have been proposed to estimate
hepatic fibrosis severity.11-13 However, simple indices that
incorporate widely available biochemical parameters such
as serum aspartate aminotransferase (AST) level and
platelet count appear to have performance characteristics
similar to the more complex serum marker panels.14-16
The utility of indices incorporating routine laboratory
tests to estimate hepatic fibrosis severity in a large AA
group with HCV has not been reported.
The Viral Resistance to Antiviral Therapy of Chronic
Hepatitis C (Virahep-C) study was a multicenter study
aimed at identifying the mechanisms of nonresponse and
antiviral resistance among AA and CA patients with pre-
viously untreated HCV genotype 1 infection.17 The aim
of the current analysis was to compare hepatic fibrosis
severity between the 194 AA and 205 CA patients en-
rolled in Virahep-C in order to identify factors associated
with severe fibrosis in the two racial groups and to devise
a simple model incorporating readily available clinical and
laboratory features to estimate the presence of severe he-
patic fibrosis. This model was developed using the Vira-
hep-C cohort and subsequently validated in an
independent cohort of 461 well-characterized, previously
untreated patients with chronic hepatitis C seen at the
NIH clinical center.18
Patients and Methods
Patient Population. The Virahep-C study was con-
ducted at 8 clinical centers in the United States with anal-
yses performed by the Data Coordinating Center at the
University of Pittsburgh (Pittsburgh, PA).17 Inclusion cri-
teria for the main trial included having detectable HCV
RNA in serum, being HCV genotype 1, having had no
previous interferon therapy, and being between 18 and 70
years of age. All subjects had to identify themselves by race
as either Black/African American or White/Caucasian
American, but not both, and as having been born in the
United States. Another inclusion criterion was having had
a pretreatment liver biopsy within 18 months of screening
whose results were consistent with chronic hepatitis C.
Patients with cirrhosis or transition to cirrhosis were re-
quired to have no evidence of decompensation or hepato-
cellular carcinoma on imaging and a serum alpha-
fetoprotein level of less than 100 ng/mL within 6 months
of entry. Exclusion criteria included pregnancy, detect-
able hepatitis B surface antigen or anti-HIV, serum creat-
inine greater than 1.5  the upper limit of normal,
anemia, and a platelet count of less than 75,000 cells/mL.
Subjects with evidence of recent alcohol or drug abuse or
severe psychiatric disorder were excluded, as were subjects
who reported consuming more than 2 alcoholic beverages
per day. All study participants signed a written informed
consent approved by the local institutional review board.
Targeted enrollment for this study was 200 AA patients
and 200 CA patients with HCV genotype 1. The current
analysis focused on the 194 AA and 205 CA Virahep-C
participants who had an interpretable liver biopsy.
Baseline Assessment. All eligible subjects underwent
a complete history and physical examination. The pre-
sumed duration of HCV infection was estimated from
information provided in patient interview about the ear-
liest parenteral exposure to HCV such as injection drug
use or blood transfusion. Subjects were asked how much
alcohol and cigarettes they consumed both currently and
in the past.19 Pretreatment complete blood count with
platelets and serum AST, alanine aminotransferase
(ALT), alkaline phosphatase, total bilirubin, and creati-
nine levels as well as alpha-fetoprotein, international nor-
malized ratio (INR), fasting serum iron studies and
cholesterol and triglyceride levels were determined at local
clinical laboratories. Serum HCV RNA levels were deter-
mined at a central laboratory (SeraCare BioServices,
Gaithersburg, MD) using the COBAS Amplicor Hepati-
tis C Virus Monitor Test, version 2.0 assay (sensitivity
600 IU/mL; Roche Molecular Diagnostics, Alameda,
CA). Samples testing negative using this quantitative as-
say were tested in duplicate with the Amplicor assay (sen-
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sitivity 50 IU/mL; Roche). HCV genotyping was
performed using the VERSANT HCV Genotype Assay
(Bayer, Tarrytown, NY), a line probe hybridization assay.
Liver Histopathology. All available liver biopsy spec-
imens were reviewed by a hepatopathologist (D.K.) who
was unaware of any clinical and demographic informa-
tion. Masson trichrome and hematoxylin and eosin stains
were reviewed for hepatitis stage and grade according to
the criteria of Ishak et al.20 and the METAVIR scoring
system.21 To control for biopsy size, the length of the
biopsy was measured with a hand ruler, and all portal
areas on one cross section were counted. Width was cate-
gorized on the basis of the apparent average width of the
biopsy core as less than 0.55 mm, 0.55-1.1 mm, or more
than 1.1 mm. Severe fibrosis was defined as an Ishak fi-
brosis score of 3 or more, which corresponds to a META-
VIR fibrosis stage of F2 or higher.
National Institutes of Health Validation Cohort.
The laboratory and clinical parameters of 494 previously
untreated patients with chronic hepatitis C seen at the
NIH Clinical Center between 1980 and 2003 were re-
cently described.18 A subgroup of 461 patients who had
laboratory parameters obtained within 6 months of their
liver biopsy were utilized for validation of the Virahep-C
fibrosis model. Patient ethnicity was self-reported by the
patients when seen at the NIH. The same hepatopatholo-
gist (D.K.) scored all the Virahep-C and NIH liver biopsy
samples. HCV genotyping was done in 331 subjects, in-
cluding 272 patients with genotype 1.
Data Analyses. Racial differences in the distributions
of baseline laboratory results and demographic factors
were tested using Student t test or the Wilcoxon rank sum
test for continuous variables and either Pearson’s chi-
square test for nominal variables or the Jonckheere-Terp-
stra test for ordinal categorical variables. Multiple logistic
regression was employed to model Ishak fibrosis  3 as a
function of pretreatment laboratory results and demo-
graphic factors. To assess and correct for potential biopsy
inadequacy in estimating fibrosis severity (e.g., understag-
ing), the number of portal areas (10 or fewer vs. at least
11) was included in the multiple logistic regression
model. To predict severe fibrosis in the model, the num-
ber of portal areas was included in the constant term to
adjust for adequacy of biopsy size.
The area under the receiver operating characteristic
(AUROC) curve was computed for the Virahep-C fibro-
sis model and compared to other published models in-
cluding the AST to platelet ratio index (APRI), the AST/
ALT ratio, and the cirrhosis discriminant score
(CDS).15,22-27 The AUROCs were compared using the
method of DeLong et al.28,29 The APRI (AST level/
[ULN]/platelet count [109/L]  100) optimally predicts
Ishak fibrosis of at least 3 with a cutoff of 0.80.15 An
AST/ALT ratio greater than 1.0 has been proposed as a
useful marker of cirrhosis (Ishak fibrosis  5) but is a poor
predictor of severe fibrosis.22,23 The CDS is a combina-
tion of the platelet count, ALT/AST ratio, and INR with
a cutoff of at least 8 that has a high specificity for severe
fibrosis.24 Finally, the age-platelet index (AP index) com-
bines patient age and platelet count into a score of 1-10.25
To compare the AUROCs of independent samples (i.e.,
AA vs. non-AA, CA vs. AA), a Wilcoxon rank sum test
was used. For all analyses, P values less than .05 were
interpreted as statistically significant. Both SAS and the R
statistical programming language were used.
Results
Virahep-C Patient Population. HCV RNA levels
were similar in the 194 AA and 205 CA patients (Table
1). The distribution of parenteral risk factors was similar
between AAs and CAs (injection drug use 48% vs. 52%,
blood products 22% vs. 24%, unknown 13% vs. 14%,
intranasal cocaine 8% vs. 4%, and other 8% vs. 7%) as
was the estimated duration of infection. Pretreatment se-
rum AST, ALT, albumin, and bilirubin levels were signif-
icantly lower in AA patients than in CA patients. In
contrast, serum alkaline phosphatase and ferritin levels
were significantly higher. Female AA patients had a higher
body weight and BMI than female CA patients, but these
parameters were not statistically significantly different be-
tween AA and CA men. Diabetes mellitus and hyperten-
sion were significantly more common among AA patients
than among CA patients.
A broad distribution of hepatic fibrosis scores was ob-
served in the Virahep-C population (Fig. 1). The Ishak
fibrosis scores were not significantly different between the
AA and CA patients (P  .45). In addition, the propor-
tion of patients with Ishak fibrosis  3 (39% CA vs. 35%
AA, P  .47) was not significantly different between the
two racial groups.
Univariate Models to Predict Ishak Fibrosis > 3.
Simple logistic regression models were used to assess the
relationship of demographic, pretreatment laboratory,
and clinical factors with severe hepatic fibrosis. Both hy-
pertension and diabetes mellitus were positively associ-
ated with severe fibrosis, whereas smoking and alcohol
consumption were not (Table 2). Age was positively asso-
ciated with severe hepatic fibrosis, but race and gender
were not. The probability of severe fibrosis increased with
increasing values of serum AST, ALT, alkaline phospha-
tase, total bilirubin, ferritin, and INR. In contrast, the
probability of severe fibrosis decreased with increasing
platelet count and cholesterol and albumin levels.
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Liver Biopsy Size and Probability of Severe Fibro-
sis. Because previous reports have demonstrated that
small liver biopsy samples may underestimate the severity
of hepatic fibrosis, severe fibrosis was analyzed as a func-
tion of biopsy size.30,31 The median length, width, and
number of portal areas in the biopsies were similar in AA
and CA patients (Table 3). However, the number of por-
tal areas was significantly associated with severe fibrosis,
Table 1. Baseline Features of the Virahep-C Study Population
Caucasian Americans African Americans
P *n n
Demographics
Age (yrs) 48 (43, 52) 205 49 (45, 52) 194 .0810”
% Male 65.4 134 64.4 125 .9281
Years of infection ** 27 (19, 33) 158 25 (17, 32) 143 .1396”
Laboratory parameters & histology
Log HCV RNA 6.30.8 205 6.20.7 192 .3754^
% Genotype
1, NOS 7.8 16 5.7 11 .3778
1a 57.8 118 46.4 90 .0288
1b 28.4 58 46.4 90 .0003
1a/1b 5.9 12 1.5 3 .0447
Serum ALT (IU/L)1 74 (51, 138) 205 59.5 (40, 90) 194 .0001‘
Serum AST (IU/L)1 52 (37, 87) 205 51 (34, 69) 194 .0164‘
Alk phosphatase (IU/L)1 77 (61, 95) 205 81 (63, 107) 194 .0364‘
Albumin (g/dl) 4.20.3 205 4.00.3 194 .0001^
Total bilirubin (mg/dL)1 0.7 (0.5, 0.9) 205 0.6 (0.4, 0.8) 194 .0005^
INR 1.0 (0.9, 1.1) 204 1.0 (0.9, 1.1) 193 .8569”
White blood cell count (103/mL)1 6.2 (4.9, 7.4) 204 5.8 (4.7, 7.5) 194 .0710^
Platelet count (103 / mL)1 206.5 (161.5, 244) 204 214.5 (168, 268) 194 .1044^
Ferritin (mg/dl)1 149 (75, 292) 203 244 (109, 413) 193 .0001^
% Iron/ TIBC  100 34.1 (26.7, 46.1) 202 33.9 (25.7, 41.3) 189 .1163”
Total cholesterol (mg/dL)1 174 (153, 197) 202 175 (152, 196) 191 .7661^
Triglycerides (mg/dL)1 97.5 (75, 137) 184 110 (76, 165) 182 .0420^
Ishak fibrosis score .4473
0 10.7 22 10.3 20
1 23.4 48 26.8 52
2 27.3 56 28.4 55
3 20.0 41 17.0 33
4 9.3 19 12.4 24
5 3.9 8 2.1 4
6 5.4 11 3.1 6
% Ishak score 3 38.5 79 34.5 67 .4683
Total HAI Inflammation 9 (7, 11) 205 8 (7, 10) 194 .2919”
Days between biopsy and baseline 103 (25, 241) 205 66 (19, 200) 194 .2325”
Clinical features
Male weight (kg) 87.3 (78.0, 99.8) 134 90.3 (79.8, 103.9) 123 .2467”
Female weight (kg) 68.5 (60.3, 82.1) 71 82.1 (73.0, 96.6) 69 .0001”
BMI (kg/m2)
Males2 28.4 (25.8, 31.4) 134 28.5 (26.2, 32.4) 123 .1759^
Females2 25.0 (22.3, 31.7) 69 31.6 (26.9, 35.3) 68 .0001‘
% Diabetes 4.4 9 15.5 30 .0004
% Hypertension 21.0 43 43.3 84 .0001
% Current smoker 34.5 70 41.5 78 .1859
Alcohol Use (drinks/day)
1 88.6 178 87.7 164 .9174
1 to 2 7.0 14 5.4 10 .6527
 2 4.5 9 59.1 13 .4047
NOTE. All statistics reported as “mean  SD”, “median (interquartile range), or “%”.
Abbreviations: NOS, Not otherwise specified
*For continuous or ordinal variables, P refers to comparisons of African American vs Caucasian American using a pooled variance estimator t-test (^), Satterthwaite
method t-test (‘), a Wilcoxon rank sum test (“), or an Exact Jonckheere-Terpstra test (). For categorical variables, P refers to a continuity adjusted chi-square test.
T-tests conducted on transformed scales are noted:
1Transformation: natural logarithm;
2 Transformation: 1 – reciprocal
**Estimated from patient interview of earliest parenteral risk factor
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with biopsies having fewer than 11 portal areas less likely
to demonstrate severe fibrosis (Fig. 2). Although liver bi-
opsy length was strongly associated with the number of
portal triads (r  0.853, P  .0001), univariate and mul-
tivariate analyses did not show a significant relationship
between biopsy length and the probability of severe fibro-
sis on (data not shown).
Multivariable Models to Predict Ishak Fibrosis >
3. The results of the simple logistic regression analyses
were used to guide the construction of the multiple logis-
tic regression model. To make use of all the biopsies avail-
able and to simultaneously adjust for the relationship
between the number of portal areas and fibrosis score, the
number of portal areas was included as a dichotomous
variable ( 11 vs.  11). Because the number of portal
areas was related to sampling artifact (i.e., smaller biopsies
may understage fibrosis), the coefficient for the number of
Fig. 1. Distribution of Ishak fibrosis scores in AA and CA patients with
HCV genotype 1 enrolled in the Virahep-C study.
Table 2. Single Explanatory Factor Models for Predicting Severe Hepatic Fibrosis in the Virahep-C Cohort
Single Explanatory Factor*
Ishak Fibrosis
0 - 2 (n  253)
Ishak Fibrosis
3-6 (n  146)
Odds Ratio
(95 % CI) P **
Age (years) 47 (42, 51) 50 (46, 53) 1.72 (1.36-2.17) .0001
% Male 62.5 69.2 1.35 (0.87-2.08) .1756
% Caucasian American 49.8 54.1 1.19 (0.79-1.79) .4072
Years of infection 24 (16, 32) n  193 27.5 (22.5, 33) n  108 1.53 (1.18-1.97) .0011
Log HCV RNA 6.2  0.7 n  253 6.3  0.7 n  144 1.10 (0.90-1.36) .3545
ALT (IU/mL) 1 55 (41, 84) 82 (59, 138) 1.90 (1.52-2.39) .0001
AST (IU/mL) 1 45 (31, 59) 74 (50, 106) 2.67 (2.06-3.47) .0001
AST/ALT ratio 1 0.7 (0.6, 0.9) 0.8 (0.7, 1.0) 1.36 (1.10-1.67) .0040
Alk phosphatase (IU/mL) 1 75 (59, 90) 92 (73, 118) 1.97 (1.56-2.49) .0001
Albumin (g/dl) 4.2  0.3 4.0  0.4 0.69 (0.56-0.86) .0007
Total bilirubin (mg/dL) 1 0.6 (0.4, 0.8) 0.7 (0.5, 0.9) 1.75 (1.39-2.21) .0001
INR 1.0 (0.9, 1.0) n  252 1.0 (1.0, 1.1) n  145 1.74 (1.39-2.19) .0001
WBC count (103/mL) 6.1 (4.8, 7.5) n  252 5.7 (4.7, 7.3) n  146 0.93 (0.76-1.15) .5031
Platelet count (103/mL) 228.5 (189, 278) n  252 176 (142, 214) n  146 0.39 (0.30-0.51) .0001
Ferritin (mg/dL) 1 174 (77, 303) n  251 263 (136, 413) n  145 1.63 (1.30-2.05) .0001
% Iron/TIBC x 100 32.2 (25.4, 41.8) n  248 36.6 (27.8, 46.6) n  143 1.11 (0.90-1.37) .3113
Cholesterol (mg/dL) 1 179 (159, 200) 164 (146, 193) 0.72 (0.58-0.89) .0025
Triglycerides (mg/dL) 1 100 (74, 146.5) n  236 109 (79, 149) n  130 1.09 (0.88-1.34) .4532
Biopsy to baseline (days) 70 (21, 227) 90 (21, 217) 1.06 (0.86-1.29) .5874
No. of portal tracts 14 (8, 21) 18.5 (13, 26) 1.37 (1.12-1.68) .0023
% Portal tracts 10 63.6 84.2 3.06 (1.83-5.11) .0001
Biopsy length (mm) 13 (9, 22) n  251 13 (10, 20) n  146 0.93 (0.76-1.15) .5111
% Biopsy width  0.55 mm 83.7 n  251 88.4 n  146 1.48 (0.81-2.72) .2040
Weight (kg) 84.4 (73.5, 95.9) n  252 85.3 (77.1, 99.3) n  145 1.26 (1.02-1.54) 0.0288
Male 87.1 (78.5, 99.3) 90.5 (79.8, 104.6) 1.24 (0.96-1.59) 0.0944
Female 78.9 (64.1, 88.5) 77.6 (68.5, 92.1) 1.17 (0.82-1.66) 0.3877
BMI (kg/m2) 2 28.3 (24.8, 32.6) n  250 28.9 (26.0, 32.3) n  144 1.13 (0.92-1.39) 0.2418
Male2 28.5 (25.9, 31.7) 28.7 (26.2, 32.0) 1.10 (0.86-1.42) 0.4500
Female2 27.2 (23.6, 34.2) 29.8 (25.6, 33.3) 1.18 (0.82-1.70) 0.3713
% Diabetes 6.7 15.1 2.46 (1.26-4.81) 0.0083
% Hypertension 24.9 43.8 2.35 (1.53-3.63) 0.0001
% Current smoker 37.7 n  247 38.2 n  144 1.02 (0.67-1.56) 0.9150
% Alcohol use 24.4 n  246 19.0 n  142 0.73 (0.44, 1.21) 0.2224
*Measures displayed as “mean  SD”, “median (interquartile range)” or “%”.
**Comparison of subjects with Ishak fibrosis 0-2 versus Ishak fibrosis 3-6. The odds ratios with 95% confidence intervals show the effect of a one standard deviation
increase in the explanatory factor on the transformed scale, if a transformation was used.
1 Natural log transform.
21- reciprocal transform.
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portal areas was included in the intercept term of the final
model, which assumed a biopsy of adequate size (i.e., 11
or more portal areas). This analysis revealed that serum
AST, platelet count, alkaline phosphatase, and age were
independently associated with severe fibrosis in the overall
study group. The final logistic regression model was:
Probability of observing severe fibrosis on an adequate
biopsy  1/(exp[y)  1) with y  5.17  0.20 
race  0.07  age (years)  1.19  ln(AST [IU/L]) 
1.76  ln(platelet count [103/mL])  1.38  ln(alkaline
phosphatase [IU/L]).
For the category of race in the model, CA was desig-
nated as 1 and AA as 0. Age was expressed in years, AST in
IU/L, platelet count in 103/mL (i.e., 210,000  210), and
alkaline phosphatase in IU/L. In multivariable analysis,
AA race was not significantly associated with severe he-
patic fibrosis (P  .45), but race was left in the model
because the main study was designed to investigate racial
differences in patients with chronic hepatitis C, and CA
patients exhibited a trend toward more severe fibrosis.
Interactions of race with patient’sage, AST, platelet
count, and alkaline phosphatase were not statistically sig-
nificant.
The overall AUROC for the model was 0.837 (95%
CI: 0.796-0.878; Fig. 3). To use the model, various cutoff
values were selected to predict whether severe fibrosis was
present. A model score (predicted probability) of at least
0.22 yielded 90% sensitivity for the presence of signifi-
cant fibrosis with a positive predictive value (PPV) of 53%
(Table 4). Similarly, a model score of  0.55 yielded 90%
specificity for the absence of significant fibrosis, with a
negative predictive value of 76%. If a model score of 
0.22 was used to predict the absence of severe fibrosis, 150
(38%) of the Virahep-C subjects would be so classified
with 90% accuracy. Similarly, using a model score greater
than 0.55 for predicting severe fibrosis would accurately
classify 99 (25%) of the Virahep-C patients with 75%
accuracy. The model would not be used to predict fibrosis
in the remaining 149 (37%) subjects, whose model scores
Table 3. Comparison of Liver Biopsy Characteristics by






Biopsy length (n  204) (n  193)
Median (IQR) (mm) 13 (9, 20) 14 (9, 20) .44961
%  15 mm 60.8 54.9 .2798
%  15 to  25 mm 27.9 30.6 .6418
%  25 mm 11.3 14.5 .4167
Biopsy width (n  204) (n  193)
%  0.55 mm 15.7 13.5 .6296
% 0.55-1.1 mm 81.4 84.5 .4954
%  1.1 mm 2.9 2.1 .7517*
No. of portal tracts (n  205) (n  194)
Median (IQR) 15 (10, 24) 15 (10, 23) .87641
%  10 29.8 27.8 .7544
% 11 to  20 39.0 38.1 .9381
%  20 31.2 34.0 .6243
1Wilcoxon rank sum test Chi-square test for percentages, except for Fisher’s
exact test (denoted by *)
^Comparison of African American and Caucasian American subjects
Fig. 2. Percentage of patients with severe fibrosis in relation to the
number of liver biopsy portal areas. Patients with a liver biopsy that
contained at least 11 portal areas had a significantly greater likelihood
of having severe fibrosis than those with a biopsy containing fewer than
11 portal areas (43% vs. 20%, P  .0009). However, there was no
significant increase in the likelihood of severe fibrosis among patients
who had a biopsy that contained 11-15 portal triads compared to those
whose biopsies had 16-20, 21-30, or 30 portal triads (P  .717).
Fig. 3. Comparison of the Virahep-C model to other published models
in estimating the presence of severe hepatic fibrosis. The AUROC of the
Virahep-C model was significantly better at estimating the probability of
severe fibrosis than the APRI (0.837 vs. 0.777, P  .0003) as well as
the AST/ALT ratio (AAR), clinical discriminant score (CDS), and age-
platelet index (AP).
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were between 0.22 and 0.55, because of the large proba-
bility of misclassification.
The utility of the Virahep-C model for both racial
groups was confirmed by fitting it separately for the AA
and CA subgroups. The AUROC was 0.845 for AA and
0.847 for CA (P  .90), indicating the Virahep-C model
is useful in estimating severe fibrosis in both racial groups.
In addition, the cutoff values for 90% sensitivity and 90%
specificity for severe fibrosis were similar for each race
(data not shown).
Other Published Models of Ishak Fibrosis > 3.
The AUROC for the 398 Virahep-C patients in the Vi-
rahep-C fibrosis model was 0.837 (95% CI: 0.796-0.878)
(Fig. 3). In comparison, the APRI model gave an AU-
ROC of 0.777 (95% CI: 0.729-0.825), so that the new
Virahep-C model predicted severe hepatic fibrosis signif-
icantly better than the APRI (P  .0003).28 The AU-
ROCs for the age-platelet index, clinical discriminant
score, and AST/ALT ratio were 0.745 (95% CI: 0.697-
0.793), 0.724 (95% CI: 0.674-0.774), and 0.576 (95%
CI: 0.516-0.635), respectively, indicating the Virahep-C
model was significantly better in this patient sample.
Use of Virahep-C Fibrosis Model in NIH Cohort.
The predictive accuracy of the Virahep-C fibrosis model
was assessed in an independent cohort of 461 patients
with chronic hepatitis C who were evaluated at the NIH
Clinical Center.18 The results of the Virahep-C model
were evaluated separately in the AA (16%) and non-AA
(84%) groups, the latter of which included CA (81%) and
Asian American (3%) patients. In the NIH cohort, the
AA patients were significantly older than the non-AA pa-
tients, and as expected, the HCV genotype 1 was more
common in the AA group (Table 5). The overall distribu-
tion of Ishak fibrosis scores and the proportion with an
Ishak fibrosis score of at least 3 were not significantly
different between AA and non-AA. However, as in the
Virahep-C population, the serum ALT and albumin lev-
els were significantly lower and the serum alkaline phos-
phatase levels were significantly higher in the AA group
than in the non-AAgroup.
The Virahep-C model had an AUROC of 0.851 in the
NIH cohort. Using a cutoff of less than 0.22 to exclude
severe fibrosis in the NIH cohort gave a specificity of 65%
and a negative predictive value of 85%. Using a cutoff
greater than 0.55 to identify patients with severe hepatic
fibrosis resulted in a sensitivity of 51% with a PPV of
81%. The Virahep-C model predicted severe hepatic fi-
brosis in the NIH cohort better than the AST/ALT ratio
(AUROC  0.556, P  .0001), AP index (AUROC 
0.722, P  .0001), and the APRI (AUROC  0.83, P 
.057). The Virahep-C model also performed significantly
better in the AA subgroup than in the non-AA subgroup
(AUROC 0.952 vs. 0.832, P  .0001). In addition, the
Virahep-C model predicted severe hepatic fibrosis signif-
icantly better in the AA subgroup (P  .001) than did the
AST/ALT ratio (0.563), the AP index (0.754), and the
APRI (0.881). In the non-AA subgroup, the Virahep-C
model was significantly better than the AST/ALT ratio
(0.544) and the AP index (0.714) and predicted fibrosis as
well as the APRI model (AUROC 0.832 vs. 0.830, P 
.85).
Discussion
The primary aim of this analysis was to compare the
severity of hepatic fibrosis prior to treatment in large

















AA & CA 398 252 146
 0.22 150(38) 135 (54) 15 (10) 54 90
 0.22 248 (62) 117 (46) 131 (90) 90 53
 0.55 299 (75) 227 (90) 72 (49) 90 76
 0.55 99 (25) 25 (10) 74 (51) 51 75
AA 194 127 67
 0.22 78 (40) 72 (57) 6 (9) 57 92
 0.22 116 (60) 55 (43) 61 (91) 91 53
 0.55 152 (78) 117 (92) 35 (52) 92 77
 0.55 42 (22) 10 (8) 32 (48) 48 76
CA 204 125 79
 0.22 76 (37) 69 (55) 7 (9) 55 91
 0.22 128 (63) 56 (45) 72 (91) 91 56
 0.55 145 (71) 110 (88) 35 (44) 88 76
 0.55 59 (29) 15 (12) 44 (56) 56 75
Abbreviations: PPV, positive predictive value; NPV, negative predictive value; AA, African American; CA, Caucasian American.
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groups of AA and CA patients with chronic hepatitis C,
HCV genotype 1. The distribution of Ishak fibrosis scores
was similar in the two racial groups, as was the proportion
of patients with severe fibrosis and cirrhosis (Fig. 1).
However, AA patients had significantly lower serum AST,
ALT, and bilirubin levels and higher serum alkaline phos-
phatase levels than did CA patients (Table 1). Of interest,
similar racial differences in laboratory parameters were
found in an independent patient population (Table 5),
and similar findings have also been reported in previous
retrospective analyses of AA cohorts with chronic hepati-
tis C.4,5 Despite the AA patients consistently having se-
rum ALT and AST levels that were lower than those of
CA patients, this and other prospective multicenter trials
have found similar levels of hepatic inflammation and
fibrosis in AA and CA treatment candidates with HCV
genotype 1.7,8 Taken together, these studies suggest that
the severity of underlying liver disease may be underesti-
mated by the ALT and AST levels in AA patients.4-6
Why the AA patients in the Virahep-C and NIH co-
horts had higher serum alkaline phosphatase levels than
the CA patients is not clear. Alkaline phosphatase levels
are usually normal in patients with chronic hepatitis C,
unless there is advanced fibrosis or cirrhosis. In the Vira-
hep-C patients, serum alkaline phosphatase level was pos-
itively associated with subject age and INR (P  .006)
and inversely associated with platelet count and albumin
level (P  .0001), suggesting that alkaline phosphatase
level correlates to some extent with disease severity. Other
studies have demonstrated that serum gamma glutamyl-
transpeptidase (GGTP), another marker of cholestasis, is
also positively associated with severe fibrosis in chronic
hepatitis C patients.14 In fact, serum GGTP levels have
been incorporated into several noninvasive algorithms of
fibrosis.14,32 Alkaline phosphatase elevation may also re-
flect a higher prevalence of insulin resistance or the effects
of diabetes, hypertension, or other comorbid conditions
among AA than among CA with chronic hepatitis C.33-38
Previous studies have reported that the duration of
HCV infection, alcohol consumption, and smoking are
important cofactors for fibrosis progression in chronic
hepatitis C. In this cohort, these three parameters were
distributed similarly between the AA and CA patients and
were not significantly associated with severe hepatic fibro-
sis. However, duration of infection is difficult to estimate,
and errors in estimation may obscure its association with
Table 5. Description of the National Institutes of Health External Validation Cohort of Previously







n  73 p**
Age (years) 43.6 (37.9, 50.9) 42.7 (37.4, 50.2) 45.9 (41.1, 53.1) .0050”
% Male 59.4 58.0 67.1 .1841
% Genotype 1 82.2 79.9 93.1 .0274
BMI (kg/m2)2 26.3 (23.6, 29.6) 26.0 (23.4, 29.3) 28.4 (25.6, 32.6) .001^
Serum AST (IU/L)1 57 (37, 89) 57.0 (37, 89.5) 56 (36, 83) .4181^
Serum ALT (IU/L)1 84 (51, 145) 88.0 (52.5, 154) 63 (47, 117) .0018^
Alkaline phosphatase (IU/L)1 77 (60, 94) 76 (59, 91) 89 (72, 131) .0001‘
Serum albumin (g/dL) 4.2  0.4 n  453 4.2  0.4 n  380 4.0  0.5 n  73 .0076‘
Total bilirubin (mg/dL)1 0.7 (0.5, 0.9) n  459 0.7 (0.5, 0.9) n  386 0.7 (0.6, 1.0) n  73 .0708^
Platelet count (103/mL)1 213 (175, 255) 212.5 (176, 256) 213 (173, 252) .6947^
Ishak fibrosis score .0379
0 18.9 11.0 20.4
1 23.0 21.9 23.2
2 19.3 17.8 19.6
3 16.5 21.9 15.5
4 10.0 13.7 9.3
5 7.4 6.9 7.5
6 5.0 6.9 4.6
% Ishak score 3 38.8 36.9 49.3 .0611
# portal triads 18 (12, 25) 18 (12, 26) 16 (12, 22) .0645”
% portal triads  11 82.0 82.5 79.5 .6523
NOTE. All statistics reported as “mean  SD”, “median (interquartile range)” or “%”.
Non-AA category includes Caucasian Americans and Asians.
*HCV genotype was available for 331 of the 461 patients (genotype not specified, n  130).
**Non-AA versus AA comparisons. For continuous variables, P refers to comparisons of African American vs Non-African American groups using a pooled variance
estimator t test (^), Satterthwaite method t test (‘), a Wilcoxon rank sum test (“), or an Exact Jonckheere-Terpstra test (). For categorical variables, P refers to a
continuity adjusted chi-square test. t tests conducted on transformed scales are noted:
1Transformation: natural logarithm;
2Transformation: 1 – reciprocal.
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fibrosis. In this cohort, patient age was significantly asso-
ciated with the presence of fibrosis and may have served as
a surrogate for disease duration. Smoking and alcohol
were also not significantly associated with fibrosis in this
cohort. Most enrolled patients drank little or no alcohol.
Thus, the Virahep-C cohort cannot be used to assess the
role of moderate to severe alcohol intake on hepatic fibro-
sis, and the absence of a significant association should not
be interpreted as indicating alcohol intake has no effect on
hepatic fibrosis progression in chronic hepatitis C.
An important aim of this analysis was to develop a
model to estimate the presence of severe hepatic fibrosis in
patients with chronic hepatitis C based on readily avail-
able and objective laboratory markers. A model incorpo-
rating age, serum AST, platelet count, and alkaline
phosphatase yielded an AUROC of 0.837 in predicting
severe fibrosis. These factors have been consistently found
to be associated with advanced fibrosis.23,26,39-45 The Vi-
rahep-C model was significantly more accurate in predict-
ing severe hepatic fibrosis than were several other
published models including the APRI (Fig. 3). The Vira-
hep-C fibrosis model was also better at predicting no se-
vere fibrosis.46 Specifically, using a cutoff of 0.55 led to an
estimation that 25% of Virahep-C patients had severe
fibrosis, which had a positive predictive value of 75%,
whereas with a cutoff of less than 0.22 an estimated 38%
of Virahep-C patients did not have severe fibrosis, for
which the negative predictive value was 90% (Table 4).
Overall, using the Virahep-C model could have led to the
avoidance of liver biopsy in up to 64% of patients so that
only one-third would have required biopsy to accurately
determine the presence of severe hepatic fibrosis. When
the Virahep-C fibrosis model was tested in an indepen-
dent cohort of untreated patients with chronic hepatitis
C, a similar AUROC was obtained, though the model
performed better in AA than in non-AA patients. In ad-
dition, the Virahep-C model was significantly better than
the other published models in the NIH cohort, although
the difference with APRI was of borderline significance
(P  .057).
Previous studies have suggested that a biopsy that con-
tains at least 11 portal areas and exceeds 25 mm in length
and 1.4 mm in width is required to avoid understaging of
hepatic fibrosis in hepatitis C.30,31 In addition, recent
studies have suggested that models of hepatic fibrosis per-
form better in patients whose liver biopsy sample was
larger.47,48 When an indicator for the number of portal
tracts was incorporated into the Virahep-C model, this
variable was not only a significant predictor of fibrosis in
univariate analysis but also an independent predictor in
multiple regression analysis. These data demonstrate that
the odds of severe fibrosis is lower with a smaller liver
biopsy (i.e., one with fewer than 11 portal areas) than with
a larger biopsy. The Virahep-C fibrosis model compen-
sated for variability in biopsy sample size when predicting
severe hepatic fibrosis by including in the constant the
coefficient for biopsy size. This allowed use of all the
Virahep-C biopsy data instead of having to discard the
scores from smaller biopsies. Future studies should also
assess the effect of biopsy size on model performance.
Among the strengths of the current analysis was that it
included a large number of both AA and CA patients who
were well characterized and previously untreated. The pa-
tient cohort included the full spectrum of disease severity
of chronic hepatitis C, short of advanced cirrhosis. The
study used biopsy readings from one expert hepato-
pathologist with careful determination of biopsy size and
number of portal areas. Furthermore, the availability of an
appropriate validation set provided assurance that the
findings are replicable and potentially generalizable.
Shortcomings of this study were that patients with mod-
erate to severe alcohol use were excluded as were patients
with HIV coinfection, factors that may significantly affect
disease progression. In addition, pretreatment laboratory
values were obtained locally at the 8 participating sites.
Furthermore, liver biopsies were obtained up to 18
months before the laboratory determinations. However,
routine liver biochemistries and complete blood counts
are commonly analyzed using standardized instruments.
In addition, the model performed well in the independent
patient cohort, for whom routine laboratory studies were
obtained at a single clinical laboratory and generally
within a few days of liver biopsy.18 Comparison of the
Virahep-C fibrosis model to other serum fibrosis marker
panels that presumably reflect hepatic fibrogenesis and
fibrolysis more directly is of interest and planned for the
future.11-13,47 In addition, comparison of the Virahep-C
fibrosis model to other noninvasive imaging modalities is
of interest but was not feasible when the study was initi-
ated in 2001.49
In summary, the distribution and severity of hepatic
fibrosis was similar between AA and CA patients enrolled
in the Virahep-C study despite significant differences in
several baseline clinical and laboratory parameters. The
Virahep-C cohort was used to develop a noninvasive
model for predicting severe hepatic fibrosis. This model
included age at the time of liver biopsy and laboratory
tests (i.e., serum AST, alkaline phosphatase, platelet
count) routinely performed for patients with chronic hep-
atitis C. Overall, the model performed well in the Vira-
hep-C population as well as in an independent cohort of
previously untreated patients. In addition, the model was
significantly better at predicting severe fibrosis than were
other published models of routine laboratory parameters.
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The Virahep-C fibrosis model may prove to be of value to
practicing clinicians attempting to determine the severity
of HCV. A web site for use of the model will be available
at http://www.virahepc.org.
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